Eribulin, a microtubule-targeting agent, promotes cGAS-STING signalling expression in triple-negative breast cancer cells by facilitating the cytoplasmic accumulation of mtDNA, IFN-β production, and downstream interferon-stimulated genes (Fermaintt et al., 2021). The gene discussed is CGAS; the disease is triple-negative breast carcinoma.